

Joseph N Blattman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8380408/joseph-n-blattman-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15 papers	1,628 citations	8 h-index	18 g-index
18 ext. papers	1,895 ext. citations	5.1 avg, IF	4.23 L-index

#	Paper	IF	Citations
15	Rexinoids Modulate Effector T Cell Expression of Mucosal Homing Markers CCR9 and $\alpha 4 \beta 7$ Integrin and Direct Their Migration .. <i>Frontiers in Immunology</i> , 2022 , 13, 746484	8.4	2
14	Selection influences naive CD8+ TCR- β repertoire sharing. <i>Immunology</i> , 2021 , 162, 464-475	7.8	
13	Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma. <i>Molecular Therapy - Oncolytics</i> , 2021 , 22, 539-554	6.4	8
12	The Impact of Broadly Relevant Novel Discoveries on Student Project Ownership in a Traditional Lab Course Turned CURE. <i>CBE Life Sciences Education</i> , 2019 , 18, ar57	3.4	21
11	A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. <i>Virology</i> , 2017 , 507, 242-256	3.6	4
10	Sequence-specific detection of different strains of LCMV in a single sample using tentacle probes. <i>Virology Journal</i> , 2017 , 14, 197	6.1	
9	IMST-50. DEVELOPMENT AND EXPRESSION OF A T CELL ENGAGER TARGETED TO GLIOBLASTOMA BY CHLOROTOXIN. <i>Neuro-Oncology</i> , 2016 , 18, vi97-vi98	1	
8	Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. <i>BMC Cancer</i> , 2016 , 16, 310	4.8	70
7	Progress and opportunities for immune therapeutics in osteosarcoma. <i>Immunotherapy</i> , 2016 , 8, 1233-443.8	3.8	28
6	Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination. <i>Vaccine</i> , 2016 , 34, 5629-5635	4.1	4
5	Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity. <i>Virology</i> , 2015 , 484, 153-162	3.6	5
4	Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. <i>Journal of Immunotherapy</i> , 2015 , 38, 96-106	5	129
3	Combination immunotherapy with CTLA-4 and PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma 2015 , 3, 21		122
2	Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire. <i>Frontiers in Immunology</i> , 2013 , 4, 485	8.4	100
1	Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. <i>Journal of Virology</i> , 2003 , 77, 4911-27	6.6	1135